Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients
| Image |  |
|---|---|
| Description | scientific article published on December 2010 |
| Author/s |
author: Francesco Cavazzini Massimo Breccia Pier Paolo Piccaluga Enrico Montefusco Mario Annunziata Antonella Gozzini Enrica Morra Giorgina Specchia Fabio Stagno Patrizia Pregno Valeria Santini Alessandro Isidori Emilio Usala |
| Publication date | December 1, 2010 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |